Little is known about the relationships between patient factors and the antihyperglycemic agents that have been prescribed as initial therapy by diabetes specialists for patients with type 2 diabetes. Moreover, there has been little clarification of the subsequent usage patterns and related factors that influenced the continuation or discontinuation of the drug or the addition of another drug. ...

As recommended pharmacological agents for type 2 diabetes mellitus (T2DM), Glucagon-Like Peptide 1 receptor agonist (GLP-1Ra) is highly evaluated its various beneficial effects. Among them, semaglutide (Rybelsus) has been in focus useful oral formation with hypoglycemic agent (OHA). Administration per os possible due to the developed technique of absorption enhancer sodium N-(8-[2-hydroxybenzoy...

We investigated the effect of aging on the level of glycosylated hemoglobin (HbA1) in healthy subjects and diabetic patients. On the basis of our findings in this study, and using the HbA1c level as an index to long-term plasma glucose control, we compared it with the levels of fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG) in different age groups subjected to different the...

This study empirically analyzes the effect of hospital competition on prescribing behaviors of oral hypoglycemic agents (OHAs) for ambulatory care in a market setting where hospitals are classified into three levels according to Taiwan' s accreditation system. Without distinguishing the types of market structures and hospital levels, there might be no significant relationship between hospital c...

The Central Indiana Beacon Community leads efforts for improving adherence to oral hypoglycemic agents (OHA) to achieve improvements in glycemic control for patients with type 2 diabetes. In this study, we explored how OHA adherence affected hemoglobin A1C (HbA1c) level in different racial groups. OHA adherence was measured by 6-month proportion of days covered (PDC). Of 3,976 eligible subjects...

PURPOSE The objective of this study was to investigate clinical and laboratory parameters that could predict which patients could maintain adequate glycemic control after switching from initial insulin therapy to oral hypoglycemic agents (OHAs) among patients with type 2 diabetes (T2D). MATERIALS AND METHODS We recruited 275 patients with T2D who had been registered in 3 cohorts of initiated ...

Background: Vildagliptin/Metformin (EquMet) and imeglimin (Twymeeg) are effective oral hypoglycemic agents (OHAs) for patients with type 2 diabetes (T2D). Case Presentation: The patient was a 68-year-old male T2D fatty liver several years. In November 2022, his HbA1c had increased to 8.2%, he started on Twymeeg, followed by EquMet. Results: Over the course of four months, patient’s value succes...

BACKGROUND Little or no research has determined the effect of vitamin D3 supplementation in conjunction with pharmacological and non-pharmacological approaches in the diabetes mellitus type 2 (DMT2) patients. The objective of this study was to determine the effect of vitamin D3 supplementation in a cohort of Saudi DMT2 population on diet, insulin and/or different oral hypoglycemic agents and co...